Can chronic spontaneous urticarial produce symptoms of neuropathic pain?^☆

Abstract

Background

Chronic spontaneous urticaria (CSU) is a condition that is associated with recurrent pruritic hives and/or angioedema lasting for more than 6 weeks and is known to affect 1% of the population. Neuropathic pain can be defined as abnormal pain in the peripheral or central nervous system following injury and results from dysfunctions in the peripheral or central nervous system without peripheral nociceptor stimulation. Histamine appears in the pathogenesis of both the CSU and diseases of the neuropathic pain spectrum.

Objective

To evaluate the symptoms of neuropathic pain in patients with CSU using scales.

Method

Fifty-one patients with CSU and 47 sex- and age-matched healthy controls were included in the study.

Results

The results of the short-form McGill Pain Questionnaire revealed the scores in the sensory and affective domains, Visual Analogue Scale (VAS) scores and pain indices to be significantly higher in the patient group (p < 0.05 for all cases), while the overall pain assessment and sensory assessment based on the Self-Administered Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) pain scale were also significantly higher in the patient group. Based on the assumption that scores of > 12 indicated neuropathy, 27 (53%) of the patients in the patient group and 8 (17%) in the control group were found to have neuropathy (p < 0.05).

Study limitations

Cross-sectional study, small patient sample and use of self-reported scales.

Conclusion

In addition to itching, patients with CSU should be aware of the potential for the association of neuropathic pain. In this chronic disease that is known to affect the quality of life, using an integrated approach with the patients and identifying accompanying problems are as important as treating the dermatological disorder.

Keywords
Chronic spontaneous urticarial; Neuropathic pain; Pruritus

Introduction

Chronic spontaneous urticaria (CSU) is a condition that is associated with recurrent pruritic hives and/or angioedema lasting for more than 6 weeks, and is known to affect 1% of the population.¹ Drugs, foods, food additives, infections (bacterial, viral, and fungal), parasitic infestations, allergens and malignancies have all been identified in the etiology of CSU, although the cause cannot be identified in 50% of cases.²,³ Vasoactive mediators released from dermal mast cells play a key role in the pathogenesis of CSU. Despite the presence of eicosanoids, cytokines and proteases, histamine is the major cytokine affecting the H1 (85%) and H2 receptors (15%) in the skin. The binding of histamine to H1 receptors causes pruritus (stimulation of C fibers) while binding to the receptors in capillaries leads to vasodilation, increased vascular permeability and edema.⁴

Neuropathic pain can be defined as abnormal pain in the peripheral or central nervous system following injury and results from dysfunctions in the peripheral or central nervous system without peripheral nociceptor stimulation.⁵ Neuropathic pain is a common problem in clinical practice and can be challenging to diagnose due to methodological differences in definition and assessment, although its estimated prevalence is 7%-10% in the general population.⁶ The mechanisms of pain formation are highly diverse and have yet to be fully clarified. Recent studies have reported that mast cells accumulate around nerve sheaths and play a role in the pathophysiology of neuropathic pain by secreting a wide variety of cytokines, including histamine.⁷

Histamine appears in the pathogenesis of both the CSU and neuropathic pain spectra of disorders. The present study investigates the symptoms of neuropathic pain in patients with CSU using scales, as the simplest and easiest method.

Method

Study sample

This cross-sectional, questionnaire-based and case-controlled study was approved by the local ethics committee (Decree nº 2017-KAEK-189_2019.07.10_04) and was conducted in accordance with the principles of the Declaration of Helsinki.

After obtaining their informed consent, 51 patients with CSU and 47 sex- and age-matched healthy controls were included in the study. All of the participants were above the age of 18 years. Excluded from the study were those with pregnancy, lactation, alcohol consumption, presence of a major central nervous system disease, cognitive impairment and psychiatric comorbidity. Only CSU patients were included in the study. Patients with chronic inducible urticaria and acute urticaria were excluded.

The body weight and height measurements were obtained for the calculation of Body Mass Index (BMI), as well as sociodemographic data, disease duration, comorbid diseases, drug use, presence of angioedema and clinical examination results of patients with CSU presenting to dermatology outpatient clinics.

Measurements

Urticaria Activity Score for 7 consecutive days (UAS7)

Is an established and widely accepted patient-reported outcome tool for the prospective measurement of CSU activity. UAS7 scores of ≤ 6 indicate well-controlled, 7-15 mild, 16-27 moderate and 28-42 severe urticarial.⁸

The short-form McGill Pain Questionnaire (SF-MPQ)

The main component of the SF-MPQ comprises 15 descriptors (11 sensory; 4 affective) that are rated on an intensity scale of 0 = none, 1 = mild, 2 = moderate or 3 = severe, and three pain scores are derived from the sum of the intensity rank values of the words chosen for sensory, affective and total descriptors. The SF-MPQ also includes the Present Pain Intensity index of the standard MPQ and a Visual Analogue Scale (VAS).⁹

The Self-Administered Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) Questionnaire

Aims to identify the pain of predominantly neuropathic origin, distinct from nociceptive pain, without the need for clinical examination. The S-LANSS is a 5-item questionnaire related to symptoms of pain and with two items related to clinical signs involving self-administered sensory tests for the presence of allodynia and decreased pin-prick sensation. The scores range from 0 to 24, with a score of 12 or greater suggesting neuropathic pain. ¹⁰

The validity and reliability of the Turkish version of these scales were developed.

Data analysis

All statistical analyses were performed using the IBM SPSS Statistics (Version 20.0. Armonk, NY: IBM Corp.) software package program. Continuous variables were expressed as mean ± SD, and Student’s t-tests were used to compare the means between the two groups. For categorical variables, a Chi-Square test was used to test the differences between groups. Spearman’s correlation analysis was used for the correlation between neuropathy tests and disease characteristics. Unless otherwise stated, p < 0.05 was set as the level of significance.

Results

The study included 51 patients (36 females, 15 males) and 47 controls (27 females, 20 males), and the two groups had similar sociodemographic characteristics (p < 0.05). In the patient group, 18 were on omalizumab and 18 were on antihistamines, while the remainder were not receiving treatment at the time of admission (Table 1).

Table 1
General demographic data and clinical features of the patient group.

	Patients (n = 51)	Controls (n = 47)	p
Gender (Ratio of Female/Male)	36/15	27/20	0.208
Age (median 25-75pr)	41 (29‒53)	39 (31‒53)	0.862
BMI (median 25-75pr)	26.72 (23.50‒31.25)	26.12 (23.23‒30.81)	0.644
Education status, n (%)			0.506
Primary school	18 (35.3%)	11(23.4%)
Secondary school	4 (7.8%)	4 (8.5%)
High school	10 (19.6%)	8 (17%)
University	19 (37.3%)	24 (50%)
Additional disease, n (%)			0.982
Hypertension	5 (9.8%)	4 (8.5%)
Diabetes mellitus	6 (11.8%)	5 (10.6%)
Guatr	8 (15.7%)	6 (12.8%)
Others	3 (5.9%)	2 (4.3%)
Disease duration (years)	3 (1‒9)	‒	‒
Urticaria activity score (median 25-75pr)	28 (14‒28)	‒	‒
Finding of angioedema (n)	20 patients	‒	‒
Therapy of urticeria
None	15 (29.4%)	‒	‒
Antihistaminic	18 (35.3%)
Omalizumab	18 (35.3%)

BMI, Body Mass Index; p < 0.05 statistically significant.The findings were given as median and interquartile range (25p‒75p).

An assessment of the results of the short-form McGill Pain Questionnaire revealed the scores in the sensory and affective domains, VAS scores and pain indices to be significantly higher in the patient group (p < 0.05 for all cases), while the overall pain assessment and sensory assessment based on the S-LANSS pain scale were also significantly higher in the patient group. Based on the assumption that scores of > 12 indicated neuropathy, 27 (53%) of the patients in the patient group and 8 (17%) in the control group were found to have neuropathy (p < 0.05). An analysis of the results of the questionnaire revealed the median total neuropathy score in the patient group to be 14, which was statistically compatible with the neuropathy findings (range: 0-33) (Table 2).

Table 2
Evaluation of McGill pain scale short form questions and S-LANSS pain questionnaires in groups.

	Patients (n = 51)	Controls (n = 47)	p
McGill pain questionnaires
Sensory score	7 (3.75‒16.5)	0 (0‒3)	0.000
Perceptual score	2 (0‒6)	0 (0‒1)	0.000
Index of pain	11 (6‒14.25)	0 (0‒4)	0.000
VAS	0 (0‒6)	0 (0‒3)	0.001
S-LANSS pain questionnaires
Pain questionnaires	11 (6‒14.25)	0 (0‒4)	0.000
Sensory evaluation	3 (0‒8)	0 (0‒0)	0.001
Total score	14 (6‒22)	0 (0‒5)	0.000
Neuropathy accompanying person, n (%)	27 (53%)	8 (17%)	0.000

VAS, Visual Analog Scale. The findings were given as median and interquartile range (25p‒75p).

An analysis of the correlations between the disease activation findings (duration of disease, frequency of attacks, urticaria activity score, and presence of angioedema) and neuropathy revealed a statistically strong positive correlation, especially with the urticaria activity score (p < 0.001, rho range: 0.524-0.969) (Table 3).

Table 3
Correlation between disease duration, attack frequency, urticaria activity score, finding of angioedema and neuropathy tests.

	Sensory score	Perceptual score	Index of pain	VAS	Pain questionnaires	Sensory evaluation	Total score
	p/rho	p/rho	p/rho	p/rho	p/rho	p/rho	p/rho
Disease duration	0.335	0.174	0.656‒0.065	0.464	0.656‒0.065	0.798‒0.037	0.738‒0.048
	0.139	0.195		0.105
Attack frequency	0.510	0.596	0.300	0.990‒0.002	0.300	0.842	0.468
	0.095	0.077	0.150		0.150	0.029	0.105
Urticaria activity score	0.000	0.000	0.000	0.000	0.000	0.000	0.000
	0.572	0.524	0.969	0.533	0.969	0.894	0.523
Finding of angioedema	0.293	0.307	0.097	0.992	0.097	0.293	0.222
	0.152	0.147	0.238	0.001	0.238	0.152	0.121

Spearman's correlation analysis.

Fig. 1 presents a bar chart of the patient and control group symptoms according to the McGill Questionnaire items. As can be seen from the chart, the descriptors that were statistically strongly significant were aching, heavy, hurtful, gnawing and hot burning (p < 0.001 for all). As for the affective domain, the strongest significant descriptors were tiring-exhausting (p < 0.001), sickening and fearful (p = 0.001), while others were throbbing (p = 0.195), shooting (p = 0.591), stabbing (p = 0.041), sharp (p = 0.042), cramping (p = 0.591), splitting (p = 0.090) and punishing-cruel (p = 0.018).

Figure 1
Bar graphs of the findings according to Mcgill Pain Questionnaires in the groups.

Discussion

In the present study significantly, higher scores were identified in the sensory and affective domains of the short-form McGill Pain Questionnaire, as well as the VAS scores and pain indices in the patient group. The overall pain assessments and sensory assessments identified from the S-LANSS pain scale were also significantly higher in the patient group. Neuropathy was detected in 27 and eight of the patient and control groups, respectively. There was a statistically strong positive correlation between the urticaria activity score, and the neuropathy test scores.

Neuropathic pain is a common problem in clinical practice that affects many aspects of daily life, and that is associated with poor overall health, reduced quality of life, poor sleep, and higher levels of anxiety and depression. The quality-of-life measurements of those with chronic neuropathic pain were found to be as low as in those with depression, coronary artery disease, recent myocardial infarction or uncontrolled diabetes mellitus.¹¹

Mast cells are immunological cells that are distributed throughout different parts of the body with reported roles in several pathological conditions, such as hypersensitivity, atherosclerosis, pulmonary hypertension and infertility. There have also been studies reporting the importance of their roles in the pathogenesis of neuropathic pain of various etiologies⁷ Olsson¹² first reported the role of mast cells in neuropathic pain and demonstrated the degranulation of mast cells in epineurium, perineurium and endoneurial connective tissue in response to trauma. Subsequent studies have revealed the role of increased mast cells in the regions surrounding the nerves and their mediators (primarily histamine and 5-HT) in the etiology of neuropathic pain.¹³-¹⁵ Considering the pathogenesis of CSU, it seems likely to be mainly a mast cell-derived disease. Cytokines such as histamine and platelet-activating factor, tryptase and leukotrienes released from mast cells cause sensory nerve activation, vasodilation and plasma extravasation.¹⁶ As can be seen, mast cells appear in the etiopathogenesis of diseases such as CSU and neuropathic pain. It was hypothesized in the present study that neuropathic pain-related symptoms may be more common in patients with CSU. To the best of our knowledge, however, there has been no study addressing this subject in literature to date. Consequently, the present study is the first to evaluate the relationship between CSU and symptoms of neuropathy.

It has been well established that sensitized mast cells can cause allergies and anaphylaxis, and mast cells are also known to contribute to several biological and pathological processes, such as vascular physiology, pain, itching and cancer.¹⁷-¹⁹ Among the previous studies in the literature evaluating the relationship between dermatological diseases and symptoms of neuropathy, Di Carlo et al. examined 118 psoriatic arthritis patients and applied questionnaires through which they detected symptoms of neuropathy in 25.4% of the patients.²⁰ Garcovich et al. evaluated the neuropathic pain symptoms of 110 patients with hidradenitis suppurativa using questionnaires, and classified 33 (30%) of the 110 patients as having “likely neuropathic pain”, 32 (29.1%) with “possible neuropathic pain” and 45 (40.9%) with “unlikely neuropathic pain”. The pain and itching scores were found to be correlated, and the patients reported that their daily activities were significantly impaired due to pain. The authors emphasized the complex and multifactorial factors determining the pain phenotype in hidradenitis suppurativa.²¹ Eosinophilic perineural inflammation and abnormal mast cell innervation were demonstrated in the histopathology of the lesional and perilesional skin of patients with hidradenitis suppurativa, suggesting a potential anatomical correlate of “neuropathic” pain.²² Lipoxygenase-derived inflammatory mediators, eicosanoids and leukotriene B4 are increased in lesional skin, and are known to be inducers of peripheral inflammation and hyperalgesia.²³ In light of this information, it is no surprise that patients with hidradenitis suppurativa tend to have accompanying symptoms of neuropathic pain.

Atopic dermatitis presents with severe itching, similar to CSU, and recent studies have reported accompanying pain symptoms in addition to itching in patients with atopic dermatitis, identifying a need to question patients in this regard.²⁴-²⁶ Pain was commonly described as “burning” and “stinging” by patients with atopic dermatitis²⁶ who described their experience of itching as painful, throbbing, biting, stinging, burning, sharp, tingling, pinprick-like, and/or associated with crawling sensations.²⁴,²⁵ All these clinical characteristics support the partial (but not fully) neuropathic component of itching.

Wallis et al. examined 35 patients with pachyonychia congenital - a rare autosomal dominant disorder - and assessed the severity and type of pain, as the main symptom in these patients, through questionnaires and quantitative sensory tests. The authors reported that 62% of the patients had neuropathic pain and the rest had nociceptive pain symptoms.²⁷ Similarly, Brill et al. made a recent study of the origin of pain in patients with pachyonychia congenital in which 62 patients and 45 controls applied the McGill and Douleur Neuropathique-4 questionnaires and underwent sensory tests. The authors found that pain may be of neuropathic origin and suggested that patients could benefit from neuropathy-oriented treatments.²⁸

This study has some limitations, the main ones being its cross-sectional study design, the small patient sample and the use of self-reported scales. Comorbidities such as type 2 diabetes could be associated with neuropathic pain, but these were present in only a small proportion of the sample, and there was no difference in the comorbidities of the two groups. Furthermore, no electrophysiological screening tests could be performed, as a further limitation. The questionnaires applied can be considered valid and reliable for use in screening tests, and in some cases, they may help identify disorders that cannot be detected by electrophysiology.

Conclusion

In addition to itching, patients with CSU should be aware of the potential for accompanying neuropathic pain. In this chronic disease that is known to affect the quality of life, using an integrated approach with the patients and identifying accompanying problems are as important as treating the dermatological disorder. There is a need for prospective studies of this issue in which descriptive and methodological methods are applied together in large patient series to support the findings of the present study.

• Financial support
  None declared.
• ⋆
  Study conducted at the Faculty of Medicine, Bozok University, Yozgat, Turkey.

References

• ¹
  Dressler C, Rosumeck S, Werner RN, Magerl M, Metz M, Maurer M, et al. Executive summary of the methods report for 'The EAACI/GA2 LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update'. Allergy. 2018;73:1145-6.
• ²
  Mathelier-Fusade P. Drug-induced urticarias. Clin Rev Allergy Immunol. 2006;30:19-23.
• ³
  Zuberbier T, Maurer M. Urticaria: current opinions about etiology, diagnosis and therapy. Acta Derm Venereol. 2007;87:196-205.
• ⁴
  Viegas LP, Ferreira MB, Kaplan AP. The maddening itch: an approach to chronic urticaria. J Investig Allergol Clin Immunol. 2014;24:1-5.
• ⁵
  Ro LS, Chang KH. Neuropathic pain: mechanisms and treatments. Chang Gung Med J. 2005;28:597-605.
• ⁶
  Zilliox LA. Neuropathic Pain. Continuum (Minneap Minn). 2017;23:512-32.
• ⁷
  Kaur G, Singh N, Jaggi AS. Mast cells in neuropathic pain: an increasing spectrum of their involvement in pathophysiology. Rev Neurosci. 2017;28:759-66.
• ⁸
  Młynek A, Zalewska-Janowska A, Martus P, Staubach P, Zuberbier T, Maurer M. How to assess disease activity in patients with chronic urticaria? Allergy. 2008;63:777-80.
• ⁹
  Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987;30:191-7.
• ¹⁰
  Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. J Pain. 2005;6:149-58.
• ¹¹
  Smith BH, Torrance N, Bennett MI, Lee AJ. Health and quality of life associated with chronic pain of predominantly neuropathic origin in the community. Clin J Pain. 2007;23:143-9.
• ¹²
  Olsson Y. Degranulation of mast cells in peripheral nerve injuries. Acta Neurol Scand. 1967;43:365-74.
• ¹³
  Olsson Y. Mast cells in the nervous system. Int Rev Cytol. 1968;24:27-70.
• ¹⁴
  Parada CA, Tambeli CH, Cunha FQ, Ferreira SH. The major role of peripheral release of histamine and 5-hydroxytryptamine in formalin-induced nociception. Neuroscience. 2001;102:937-44.
• ¹⁵
  Levy D, Kainz V, Burstein R, Strassman AM. Mast cell degranulation distinctly activates trigemino-cervical and lumbosacral pain pathways and elicits widespread tactile pain hypersensitivity. Brain Behav Immun. 2012;26:311-7.
• ¹⁶
  Sánchez-Borges M, Ansotegui IJ, Baiardini I, Bernstein J, Canonica GW, Ebisawa M, et al. The challenges of chronic urticaria part 1: Epidemiology, immunopathogenesis, comorbidities, quality of life, and management. World Allergy Organ J. 2021;14:100533.
• ¹⁷
  Maurer M, Theoharides T, Granstein RD, Bischoff SC, Bienenstock J, Henz B, et al. What is the physiological function of mast cells? Exp Dermatol. 2003;12:886-910.
• ¹⁸
  Koulouris AI, Banim P, Hart AR. Pain in Patients with Pancreatic Cancer: Prevalence, Mechanisms, Management and Future Developments. Dig Dis Sci. 2017;62:861-70.
• ¹⁹
  Xanthos DN, Gaderer S, Drdla R, Nuro E, Abramova A, Ellmeier W, et al. Central nervous system mast cells in peripheral inflammatory nociception. Mol Pain. 2011;7:42.
• ²⁰
  Di Carlo M, Muto P, Benfaremo D, Luchetti MM, Atzeni F, Salaffi F. The Neuropathic Pain Features in Psoriatic Arthritis: A Cross-sectional Evaluation of Prevalence and Associated Factors. J Rheumatol. 2020;47:1198-203.
• ²¹
  Garcovich S, Muratori S, Moltrasio C, Buscemi AA, Giovanardi G, Malvaso D, et al. Prevalence of Neuropathic Pain and Related Characteristics in Hidradenitis Suppurativa: A Cross-Sectional Study. J Clin Med. 2020;9:4046.
• ²²
  List EK, Pascual JC, Zarchi K, Nürnberg BM, Jemec GBE. Mast cells in hidradenitis suppurativa: a clinicopathological study. Arch Dermatol Res. 2019;311:331-5.
• ²³
  Penno CA, Jäger P, Laguerre C, Hasler F, Hofmann A, Gass SK, et al. Lipidomics Profiling of Hidradenitis Suppurativa Skin Lesions Reveals Lipoxygenase Pathway Dysregulation and Accumulation of Proinflammatory Leukotriene B4. J Invest Dermatol. 2020;140:2421-32.e10.
• ²⁴
  Huet F, Shourick J, Séité S, Taïeb C, Misery L. Pain in Atopic Dermatitis: An Online Population-based Survey. Acta Derm Venereol. 2020;100:adv00198.
• ²⁵
  Vakharia PP, Chopra R, Sacotte R, Patel KR, Singam V, Patel N, et al. Burden of skin pain in atopic dermatitis. Ann Allergy Asthma Immunol. 2017;119:548-52.e3.
• ²⁶
  Maarouf M, Kromenacker B, Capozza KL, Kempton D, Hendricks A, Tran K, et al. Pain and Itch Are Dual Burdens in Atopic Dermatitis. Dermatitis. 2018;29:278-81.
• ²⁷
  Wallis T, Poole CD, Hoggart B. Can skin disease cause neuropathic pain? A study in pachyonychia congenita. Clin Exp Dermatol. 2016;41:26-33.
• ²⁸
  Brill S, Sprecher E, Smith FJD, Geva N, Gruener H, Nahman-Averbuch H, et al. Chronic pain in pachyonychia congenita: evidence for neuropathic origin. Br J Dermatol. 2018;179:154-62.

Publication Dates

• Publication in this collection
  16 June 2023
• Date of issue
  May-Jun 2023

History

• Received
  5 Jan 2022
• Accepted
  9 June 2022
• Published
  20 Feb 2023